About PanTher Therapeutics
PanTher Therapeutics is a company based in Cambridge (United States) founded in 2014. It operates as a HealthTech. PanTher Therapeutics has raised $15.35 million across 10 funding rounds from investors including CHV, Angel Physicians Fund and state.tx.us. The company has 47 employees as of October 31, 2017. PanTher Therapeutics offers products and services including PTM-101 and Sagittari Platform. PanTher Therapeutics operates in a competitive market with competitors including Tonix Pharma, PolyPid, Onconic Therapeutics, Zyl Therapeutics and Santen Pharmaceuticals, among others.
- Headquarter Cambridge, United States
- Employees 47 as on 31 Oct, 2017
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Panther Therapeutics, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$15.35 M (USD)
in 10 rounds
-
Latest Funding Round
$3.02 M (USD), Series B
Mar 14, 2025
-
Investors
CHV
& 2 more
-
Employee Count
47
as on Oct 31, 2017
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of PanTher Therapeutics
PanTher Therapeutics offers a comprehensive portfolio of products and services, including PTM-101 and Sagittari Platform.
A chemotherapy patch for pancreatic cancer treatment developed.
Platform for creating optimized cancer drug delivery systems.
People of PanTher Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of PanTher Therapeutics
PanTher Therapeutics has successfully raised a total of $15.35M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $3.02 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PanTher Therapeutics
PanTher Therapeutics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include CHV, Angel Physicians Fund and state.tx.us.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Investment and advisory services are provided to healthcare startups.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for PanTher Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PanTher Therapeutics
Investment portfolio details for PanTher Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PanTher Therapeutics
Detailed financials for PanTher Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Panther Therapeutics Comparisons
Peer comparison for PanTher Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PanTher Therapeutics
PanTher Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tonix Pharma, PolyPid, Onconic Therapeutics, Zyl Therapeutics and Santen Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Next-generation medicines for CNS and immunological disorders are developed.
|
|
| Locked | Locked | Locked |
Technology platform enabling controlled and prolonged release of any Active Pharmaceutical Ingredient (API)
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and gastrointestinal diseases are developed.
|
|
| Locked | Locked | Locked |
Hydrogel-derived nanoparticles for topical drug delivery are developed.
|
|
| Locked | Locked | Locked |
Pharmaceutical products for ophthalmology and rheumatology diseases are manufactured.
|
Detailed competitors of PanTher Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Panther Therapeutics
Complete news archive for PanTher Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PanTher Therapeutics
PanTher Therapeutics was founded in 2014 and raised its 1st funding round 1 year after it was founded.
PanTher Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
PanTher Therapeutics is a funded company, having raised a total of $15.35M across 10 funding rounds to date.
As of Oct 31, 2017, the latest employee count at PanTher Therapeutics is 47.
PanTher Therapeutics is engaged in developing advanced cancer treatments through its proprietary Sagittari platform. The company specializes in long-lasting, high-dose local chemotherapeutic solutions for oncology, targeting tumors with minimal systemic exposure. Its lead product, PTM-101, is under clinical development for pancreatic cancer. The platform is utilized to engineer drug products for optimal dose and duration, integrated with interventional oncology procedures. Pipeline opportunities are also being explored to expand therapeutic applications in the healthcare sector.
PanTher Therapeutics's top competitors include Tonix Pharma, PolyPid and Onconic Therapeutics.
PanTher Therapeutics offers PTM-101 and Sagittari Platform.
PanTher Therapeutics has 3 investors. Key investors include CHV, Angel Physicians Fund, and state.tx.us.